Roche Holding AG (RHHBY) Shareholder/Analyst Call April 22, 2026 at 11:00 AM EST
Company participants
Bruno Eschli – Head of Investor Relations
Alexandra Goodyear
Levi Garroway – Executive Vice President, Head of Global Product Development and Chief Medical Officer
Conference call participants
Jeon Oh
Luisa Hector-Jo. Berenberg, Gosler & Company, Research Division
James Gordon – Barclays Bank PLC, Research Division
Alec Ebeling – UBS Investment Bank, Research
Sachin Jain – Bank of America Securities, Research Division
Peter Verdault – BNP Paribas, Research Division
James Quigley – Goldman Sachs Group, Research Division
Steve Scala – T.D. Quinn, Research Division
Urban Frisch – Zürcher Kantal Bank, Research Division
Presentation
Operator
My name is Henrik, and I am the technical operator for today’s call. Please note that the webinar is being recorded. (Operator Instructions) One final note, if you would like to follow along with the slides presented on your own as well, feel free to go to roche.com/investors to download the presentation.
Currently, we are pleased to introduce you to Bruno Eschli, Head of Investor Relations. Bruno, the stage is yours.
Bruno Ashley
Head of Investor Relations
Thanks, Henrik. And can I have the agenda slide, please. Welcome to our third IR event in 2026, focusing on the Phase III FENhance 1 and 2 results for fenbrutinib in RMS, which were just presented yesterday at the AAN in Chicago. Today’s call is scheduled to last 60 minutes, and the Roche team will be calling us from Chicago. Let me quickly update you on today’s agenda. We have 2 speakers with us. After the opening, the first speaker of the day will be Alexandra Goodyear. She is a physician and our Life Cycle Leader for Fenbrutinib.
Alexandra will give a quick introduction to fenbrutinib and how this molecule really stands out from other BTKs that were late in MS development. You will
